Table 2.
Prevalence of CTCs at baseline (T0) and follow-up (T1) as detected by the metabolism-based assay (MBA) and CellSearch (CS), according to the cut-off of 6 and 5 CTCs, respectively. (HD = healthy donor volunteers; mBC = metastatic breast cancer patients).
| Cohort | N | Mean ± SD | Median | Range | % of Patients with CTCs Above Cut-Off |
|---|---|---|---|---|---|
| MBA | |||||
| HD | 26 | 0 ± 1 | 0 | 0–5 | 0% |
| mBC at T0 | 27 | 218 ± 1022 | 0 | 0–5319 | 37% |
| mBC at T1 | 26 | 37 ± 75 | 4 | 0–280 | 30.7% |
| CS | |||||
| mBC at T0 | 22 | 129 ± 433 | 3 | 0–2022 | 36.4% |
| mBC at T1 | 22 | 22 ± 65 | 1 | 0–288 | 22.7% |